ARROWHEAD PHARMACEUTICALS, INC. ARWR
The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year.
The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS"). Additionally, phase 3 studies (SHASTA-3, SHASTA-4 and SHASTA-5) for severe hypertriglyceridemia ("sHTG") have been fully enrolled and the Company plans to file a supplemental NDA for this indication in 2026, pending successful completion of Phase 3 clinical studies. The Company has built a commercial organization to support marketing in FCS, a rare disease, and plans to progressively build its commercial capabilities to also support marketing in sHTG, a higher prevalence disease which will require a larger commercial footprint.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M | $88.0M | $168.8M | $16.1M | $31.4M | $158.3K |
| R&D | $607.2M | $505.9M | $353.2M | — | — | — | — | — | — | — |
| SG&A | $123.9M | $98.8M | $92.5M | $124.4M | $81.0M | $52.3M | $26.6M | $19.1M | $17.5M | $23.6M |
| Total operating expenses | $731.1M | $604.6M | $445.7M | $421.7M | $287.3M | $181.2M | $107.6M | $72.1M | $68.4M | $81.9M |
| Operating income | $98.3M | -$601.1M | -$205.0M | -$178.5M | -$149.0M | -$93.2M | $61.2M | -$55.9M | -$37.0M | -$81.7M |
| Interest expense | $89.4M | $32.4M | $18.3M | $0 | $0 | — | — | — | — | — |
| Pre-tax income | $51.5M | -$612.5M | -$206.5M | -$172.7M | -$140.8M | -$84.6M | $68.1M | -$54.4M | -$34.4M | -$81.7M |
| Income tax | $21.4M | $2.8M | $2.8M | $3.8M | $2.0K | $2.0K | $174.0K | $2.4K | $2.4K | $2.4K |
| Net income | -$1.6M | -$599.5M | -$205.3M | -$176.1M | -$140.8M | -$84.6M | $68.0M | -$54.5M | -$34.4M | -$81.7M |
| EPS, basic | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 | — |
| EPS, diluted | -0.01 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | -0.47 | -1.34 |
| Shares, diluted (wtd. avg.) | $133.8M | $119.8M | $106.8M | $105.4M | $103.7M | $100.7M | $98.6M | $83.6M | $73.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $226.5M | $102.7M | $110.9M | $108.0M | $184.4M | $143.6M | $221.8M | $30.1M | $24.8M | $85.4M |
| Short-term investments | $692.8M | $578.3M | $292.7M | $0 | $126.7M | $85.0M | — | — | — | — |
| Receivables | $6.8M | $0 | $0 | $1.4M | $10.3M | $846.0K | $661.4K | $327.4K | $67.8K | $75.0K |
| Total current assets | $950.6M | $695.5M | $416.5M | $405.3M | $384.6M | $322.4M | $265.2M | $78.8M | $67.9M | $90.5M |
| Property, plant and equipment | $382.5M | $386.0M | $290.3M | $110.3M | $48.7M | $30.9M | $23.2M | $13.9M | $15.5M | $15.4M |
| Other intangibles | $6.9M | $8.6M | $10.3M | $12.0M | $13.7M | $15.4M | $17.1M | $18.8M | $20.5M | $22.2M |
| Total assets | $1.39B | $1.14B | $765.6M | $691.9M | $710.1M | $522.5M | $349.8M | $111.6M | $104.0M | $128.2M |
| Accounts payable | $17.7M | $11.4M | $35.9M | $2.9M | $9.5M | $6.8M | $7.6M | $2.8M | $4.1M | $12.2M |
| Total current liabilities | $195.5M | $103.2M | $105.5M | $138.8M | $146.5M | $40.7M | $97.1M | $12.4M | $18.7M | $25.6M |
| Retained earnings | -$1.63B | -$1.63B | -$1.03B | -$820.8M | -$644.7M | -$503.8M | -$419.3M | -$487.3M | -$432.8M | -$398.4M |
| Total equity | $466.1M | $185.4M | $287.2M | $418.3M | $408.8M | $461.8M | $244.0M | $95.2M | $80.9M | $95.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $179.6M | -$462.9M | -$153.9M | -$136.1M | $171.3M | -$95.8M | $173.0M | -$47.2M | -$23.9M | -$64.4M |
| Depreciation and amortisation | $22.2M | $16.9M | $10.7M | $8.7M | $6.6M | $4.2M | $2.7M | $3.0M | $3.0M | $1.5M |
| Stock-based compensation | $63.4M | $74.0M | $78.1M | $120.9M | $76.7M | $43.4M | $12.4M | $8.5M | $7.9M | $11.6M |
| Capital expenditure | $22.7M | $141.5M | $176.7M | $52.8M | $23.6M | $12.0M | $12.0M | $1.4M | $7.9M | $3.9M |
| Investing cash flow | -$129.3M | -$420.1M | -$96.2M | -$5.4M | -$141.7M | -$240.8M | -$47.7M | -$7.4M | -$48.6M | $13.4M |
| Financing cash flow | $74.0M | $870.5M | $253.1M | $65.2M | $11.3M | $257.9M | $66.4M | $60.0M | $12.1M | $55.1M |
| Buybacks | $53.2M | — | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000879407-25-000029.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |